Patents by Inventor Claudia Ferrara Koller
Claudia Ferrara Koller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10392445Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.Type: GrantFiled: March 10, 2016Date of Patent: August 27, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
-
Publication number: 20190248877Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one antigen binding moiety capable of specific binding to Tenascin-C (TnC) and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecules are characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof. The invention further relates to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: November 9, 2018Publication date: August 15, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
-
Publication number: 20190211113Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) four moities capable of specific binding to a costimulatory TNF receptor family member, (b) at least one moiety capable of specific binding to a target cell antigen, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: December 12, 2018Publication date: July 11, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Maria AMANN, Peter BRUENKER, Christina CLAUS, Claudia FERRARA KOLLER, Sandra GRAU-RICHARDS, Ralf HOSSE, Christian KLEIN, Viktor LEVITSKI, Samuel MOSER, Pablo UMANA
-
Publication number: 20190194291Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) one Fab domain capable of specific binding to a target cell antigen, (b) a Fc domain composed of a first and a second subunit capable of stable association, and (c) a first polypeptide comprising two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and a second polypeptide comprising one ectodomain of said TNF ligand family member or a fragment thereof, wherein the first polypeptide is fused at its N-terminus to the C-terminus of one of the subunits of the Fc domain and wherein the second polypeptide is fused at its N-terminus to the C-terminus of the other subunit of the Fc domain, wherein the TNF family ligand trimer-containing antigen binding molecule is monovalent for the binding to the target cell antigen.Type: ApplicationFiled: November 8, 2018Publication date: June 27, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Peter Bruenker, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Ekkehard Moessner, Pablo Umana, Maria Amann, Christina Claus, Wei Xu
-
Publication number: 20190185566Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to PD1 and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.Type: ApplicationFiled: November 13, 2018Publication date: June 20, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Claudia Ferrara Koller, Christina Claus, Christian Klein, Stefan Seeber, Maria Amann, Sandra Grau-Richards, Peter Bruenker, Pablo Umana, Viktor Levitski, Ekkehard Moessner
-
Publication number: 20190062453Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: March 6, 2018Publication date: February 28, 2019Applicant: Roche Glycart AGInventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, lnja Waldhauer, Huisheng Wang, Barbara Weiser
-
Publication number: 20190016771Abstract: The invention relates to novel trimeric costimulatory TNF family ligand-containing antigen binding molecules comprising three fusion polypeptides, each of the three fusion polypeptides comprising (a) an ectodomain of a costimulatory TNF family ligand selected from the group consisting of 4-1BBL, OX40L and GITRL or fragments thereof, (b) a trimerization domain, in particular a trimerization domain derived from human cartilage matrix protein (huCMP) of SEQ ID NO:1, and (c) a moiety capable of specific binding to a target cell antigen, and to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: September 27, 2018Publication date: January 17, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Maria AMANN, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
-
Publication number: 20180282409Abstract: Herein is reported an antibody that specifically binds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.Type: ApplicationFiled: September 30, 2016Publication date: October 4, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Claudia FERRARA KOLLER, Guy GEORGES, Alexander HAAS, Hubert KETTENBERGER, Ekkehard MOESSNER, Tilman SCHLOTHAUER, Michael MOLHOJ, Laurent LARIVIERE
-
Publication number: 20180230215Abstract: The present invention relates to antibodies against human CD19 (anti-human CD19 antibodies), methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.Type: ApplicationFiled: March 30, 2018Publication date: August 16, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Thomas HOFER, Claudia FERRARA KOLLER, Ekkehard MOESSNER, Mi HE
-
Patent number: 9975958Abstract: The present invention pertains to a trimeric antigen binding molecule comprising three fusion polypeptides, each comprising at least one antigen binding moiety fused to a trimerization domain derived from human cartilage matrix protein. In addition, the present invention relates to polynucleotides encoding such trimeric antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the trimeric antigen binding molecules of the invention, and to methods of using these trimeric antigen binding molecules in the treatment of disease.Type: GrantFiled: November 6, 2015Date of Patent: May 22, 2018Assignee: Hoffmann-La Roche Inc.Inventors: Peter Bruenker, Claudia Ferrara Koller, Sandra Grau-Richards, Ekkehard Moessner, Pablo Umana
-
Patent number: 9926379Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: April 1, 2014Date of Patent: March 27, 2018Assignee: ROCHE GLYCART AGInventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
-
Publication number: 20170247467Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) four moieties capable of specific binding to a costimulatory TNF receptor family member, (b) at least one moiety capable of specific binding to a target cell antigen, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: September 29, 2016Publication date: August 31, 2017Applicant: Hoffmann-La Roche Inc.Inventors: MARIA AMANN, PETER BRUENKER, CHRISTINA CLAUS, CLAUDIA FERRARA KOLLER, SANDRA GRAU-RICHARDS, RALF HOSSE, CHRISTIAN KLEIN, VIKTOR LEVITSKI, SAMUEL MOSER, PABLO UMANA
-
Publication number: 20170114141Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: September 29, 2016Publication date: April 27, 2017Applicant: Hoffmann-La Roche Inc.Inventors: MARIA AMANN, PETER BRUENKER, CHRISTINA CLAUS, CLAUDIA FERRARA KOLLER, SANDRA GRAU-RICHARDS, RALF HOSSE, CHRISTIAN KLEIN, VIKTOR LEVITSKI, PABLO UMANA
-
Publication number: 20160340399Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: March 31, 2016Publication date: November 24, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
-
Patent number: 9481730Abstract: The present invention relates to bispecific antibodies comprising a first antigen binding site specific for a death receptor and a second antigen binding site specific for a second antigen, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: September 27, 2010Date of Patent: November 1, 2016Assignee: Roche Glycart AGInventors: Peter Bruenker, Claudia Ferrara Koller, Sandra Grau, Sylvia Herter, Christoph Lampert, Ekkehard Moessner, Pablo Umana, Inja Waldhauer
-
Publication number: 20160200833Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.Type: ApplicationFiled: March 10, 2016Publication date: July 14, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Victor Levitsky, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
-
Publication number: 20160159917Abstract: The present invention pertains to a trimeric antigen binding molecule comprising three fusion polypeptides, each comprising at least one antigen binding moiety fused to a trimerization domain derived from human cartilage matrix protein. In addition, the present invention relates to polynucleotides encoding such trimeric antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the trimeric antigen binding molecules of the invention, and to methods of using these trimeric antigen binding molecules in the treatment of disease.Type: ApplicationFiled: November 6, 2015Publication date: June 9, 2016Applicant: HOFFMANN-LA ROCHE INC.Inventors: Peter BRUENKER, Claudia Ferrara KOLLER, Sandra GRAU-RICHARDS, Ekkehard MOESSNER, Pablo UMANA
-
Patent number: 9296820Abstract: The present invention relates to nucleic acids encoding anti-CD20 antigen binding molecules (ABMs). In particular embodiments, the present invention relates to nucleic acid encoding recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In some embodiments, the invention relates to an isolated polynucleotide comprising a) a sequence encoding a polypeptide having a sequence selected from the group consisting of SEQ ID NO:40; SEQ ID NO:32; SEQ ID NO:56; and SEQ ID NO:60; and b) a sequence encoding a polypeptide having the sequence of SEQ ID NO:76. In addition, the present invention relates to vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: GrantFiled: November 5, 2004Date of Patent: March 29, 2016Assignee: Roche GlycArt AGInventors: Pablo Umaña, Peter Brünker, Claudia Ferrara Koller, Tobias Suter, Ursula Püntener, Ekkehard Mössner
-
Publication number: 20160075794Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: July 31, 2015Publication date: March 17, 2016Inventors: Pablo UMAÑA, Peter Brünker, Claudia FERRARA KOLLER, Tobias SUTER, Ursula Püntener, Ekkehard Mössner
-
Publication number: 20160075793Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: ApplicationFiled: July 31, 2015Publication date: March 17, 2016Inventors: Pablo UMAÑA, Peter BRÜNKER, Claudia FERRARA KOLLER, Tobias SUTER, Ursula PÜNTENER, Ekkehard MÖSSNER